UB Paderborn / Katalog / Suche / in CDI

Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma

Annals of oncology, 2015-10, Vol.26 (10), p.2173-2179

2015

Volltextzugriff (PDF)

Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition

Oncogene, 2007-08, Vol.26 (38), p.5655-5661

2007

Volltextzugriff (PDF)

3124 Loss-of-function screen and mutational analysis to identify genes associated with sensitivity to veliparib and carboplatin therapy in non-small cell lung cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S644-S645

2015

Volltextzugriff (PDF)

RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors

Oncogene, 2006-03, Vol.25 (9), p.1340-1348

2006

Volltextzugriff (PDF)

Inhibitors of the protease domain of urokinase-type plasminogen activator

Current pharmaceutical design, 2002-01, Vol.8 (28), p.2541

2002

Volltextzugriff (PDF)

Discovering novel ligands for macromolecules using X-ray crystallographic screening

Nature biotechnology, 2000-10, Vol.18 (10), p.1105-1108

2000

Volltextzugriff (PDF)

Design, Synthesis, and Structural Analysis of Influenza Neuraminidase Inhibitors Containing Pyrrolidine Cores

Journal of medicinal chemistry, 2001-04, Vol.44 (8), p.1192-1201

2001

Volltextzugriff (PDF)

3091 Characterization of advanced NSCLC patients with prolonged benefit after veliparib plus carboplatin/paclitaxel: Phase 2 results

European journal of cancer (1990), 2015-09, Vol.51, p.S629-S630

2015

Volltextzugriff (PDF)

3093 Veliparib with carboplatin and paclitaxel: factors predictive of favorable outcomes in NSCLC

European journal of cancer (1990), 2015-09, Vol.51, p.S630-S630

2015

Volltextzugriff (PDF)

A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) With Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S4-S5

2014

Volltextzugriff (PDF)

An American Brain Tumor Consortium (ABTC) Phase 1 Trial of Veliparib (ABT-888), Temozolomide (TMZ), and Concurrent Radiation Therapy (RT) for Newly Diagnosed Glioblastoma Multiforme (GBM): Need for Modification to Approach for Combining These Therapies

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S7-S8

2012

Volltextzugriff (PDF)

Efficacy of Veliparib (ABT-888) Plus Temozolomide Versus Temozolomide Alone: a Randomized, Double-blind, Placebo-controlled Trial in Patients with Metastatic Melanoma

European journal of cancer (1990), 2011, Vol.47, p.8-8

2011

Volltextzugriff (PDF)

Novel α- and β-Amino Acid Inhibitors of Influenza Virus Neuraminidase

Antimicrobial Agents and Chemotherapy, 2001-09, Vol.45 (9), p.2563-2570

2001

Volltextzugriff (PDF)

Species Specificity of Amidine-Based Urokinase Inhibitors

Biochemistry (Easton), 2001-08, Vol.40 (31), p.9125-9131

2001

Volltextzugriff (PDF)

Rapamycin Inhibits Akt-Mediated Oncogenic Transformation and Tumor Growth

Anticancer research, 2004-09, Vol.24 (5A), p.2697-2704

2004

Volltextzugriff (PDF)

Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite

Structure (London), 2000-05, Vol.8 (5), p.553-563

2000

Volltextzugriff (PDF)

A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) with Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer

Annals of oncology, 2015-04, Vol.26, p.i29

2015

Volltextzugriff (PDF)

Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents

Anticancer research, 2001-01, Vol.21 (1A), p.23

2001

Volltextzugriff (PDF)

Acid-Induced Structural Changes in Human Rhinovirus 14: Possible Role in Uncoating

Proceedings of the National Academy of Sciences - PNAS, 1992-11, Vol.89 (21), p.10213-10217

1992

Volltextzugriff (PDF)

Blocking CHK1 Expression Induces Apoptosis and Abrogates the G2 Checkpoint Mechanism

Neoplasia (New York, N.Y.), 2001, Vol.3 (5), p.411-419

2001

Volltextzugriff (PDF)

Downregulation of Akt1 Inhibits Anchorage-Independent Cell Growth and Induces Apoptosis in Cancer Cells

Neoplasia (New York, N.Y.), 2001, Vol.3 (4), p.278-286

2001

Volltextzugriff (PDF)

Influenza Neuraminidase Inhibitors: Structure-Based Design of a Novel Inhibitor Series

Biochemistry (Easton), 2003-01, Vol.42 (3), p.718-727

2003

Volltextzugriff (PDF)

Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals

Cancer research (Chicago, Ill.), 2005-04, Vol.65 (7), p.2698-2704

2005

Volltextzugriff (PDF)

The protease consortium: An alliance to advance the understanding of proteolytic enzymes as therapeutic targets for cancer

Molecular Carcinogenesis, 1999-11, Vol.26 (3), p.139-142

1999

Volltextzugriff (PDF)

555 POSTER The PARP inhibitor, ABT-888 overcomes resistance in temozolomide refractory breast and prostate xenograft tumors implanted in metastatic sites in vivo

European journal of cancer supplements, 2008, Vol.6 (12), p.175-175

2008

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma

Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition

3124 Loss-of-function screen and mutational analysis to identify genes associated with sensitivity to veliparib and carboplatin therapy in non-small cell lung cancer

RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors

Inhibitors of the protease domain of urokinase-type plasminogen activator

Discovering novel ligands for macromolecules using X-ray crystallographic screening

Design, Synthesis, and Structural Analysis of Influenza Neuraminidase Inhibitors Containing Pyrrolidine Cores

3091 Characterization of advanced NSCLC patients with prolonged benefit after veliparib plus carboplatin/paclitaxel: Phase 2 results

3093 Veliparib with carboplatin and paclitaxel: factors predictive of favorable outcomes in NSCLC

A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) With Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer

An American Brain Tumor Consortium (ABTC) Phase 1 Trial of Veliparib (ABT-888), Temozolomide (TMZ), and Concurrent Radiation Therapy (RT) for Newly Diagnosed Glioblastoma Multiforme (GBM): Need for Modification to Approach for Combining These Therapies

Efficacy of Veliparib (ABT-888) Plus Temozolomide Versus Temozolomide Alone: a Randomized, Double-blind, Placebo-controlled Trial in Patients with Metastatic Melanoma

Novel α- and β-Amino Acid Inhibitors of Influenza Virus Neuraminidase

Species Specificity of Amidine-Based Urokinase Inhibitors

Rapamycin Inhibits Akt-Mediated Oncogenic Transformation and Tumor Growth

Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite

A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) with Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer

Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents

Acid-Induced Structural Changes in Human Rhinovirus 14: Possible Role in Uncoating

Blocking CHK1 Expression Induces Apoptosis and Abrogates the G2 Checkpoint Mechanism

Downregulation of Akt1 Inhibits Anchorage-Independent Cell Growth and Induces Apoptosis in Cancer Cells

Influenza Neuraminidase Inhibitors: Structure-Based Design of a Novel Inhibitor Series

Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals

The protease consortium: An alliance to advance the understanding of proteolytic enzymes as therapeutic targets for cancer

555 POSTER The PARP inhibitor, ABT-888 overcomes resistance in temozolomide refractory breast and prostate xenograft tumors implanted in metastatic sites in vivo

Suchergebnisse filtern